tbuckley/cabot-search huggingface dataset:
The PI3K-δ Inhibitor TGR-1202 In Combination With Brentuximab Vedotin (SGN-35) Synergistically Induces G2/M Phase Arrest and Cell Death Via Inhibition Of Tubulin Polymerization In Hodgkin Lymphoma Cell Lines
Authors: Silvia L Locatelli, Silvia Tartari, Luca Rubino, Ercole Brusamolino, Luca Castagna, Peter Sportelli, Armando Santoro, Carmelo Carlo-Stella
Journal: Blood (2013)
Targeting of PYK2 Synergizes with EGFR Antagonists in Basal-like TNBC and Circumvents HER3-Associated Resistance via the NEDD4–NDRG1 Axis
Authors: Nandini Verma, Anna-Katharina Müller, Charu Kothari, Effrosini Panayotopoulou, Amir Kedan, Michael Selitrennik, Gordon B. Mills, Lan K. Nguyen, Sungyoung Shin, Thomas Karn, Uwe Holtrich, Sima Lev
Journal: Cancer Research (2016)

Triple-negative breast cancer (TNBC) is a highly aggressive, heterogeneous disease with poor prognosis and no effective targeted therapies. EGFR is highly expressed in basal-like TNBC and is considered as a potential therapeutic target. However, EGFR targeting exerts only marginal clinical benefits, possibly due to activation of compensatory signaling pathways, which are frequently associated with HER3 upregulation. Here we show that concomitant targeting of EGFR and the nonreceptor tyrosine kinases PYK2/FAK synergistically inhibits the proliferation of basal-like TNBC cells in vitro and attenuates tumor growth in a mouse xenograft model. Dual targeting of EGFR and PYK2/FAK inhibited complementary key growth and survival pathways mediated by AKT, S6K, STAT3, and ERK1/2 activation. PYK2 inhibition also abrogated HER3 upregulation in response to EGFR antagonists, thereby circumventing HER3-associated drug resistance. Mechanistically, PYK2 inhibition facilitated the proteasomal degradation of HER3 while inducing upregulation of NDRG1 (N-myc downstream regulated 1 gene). NDRG1 enhanced the interaction of HER3 with the ubiquitin ligase NEDD4, while PYK2, which interacts with NEDD4 and HER3, interfered with NEDD4-HER3 binding, suggesting that the PYK2-NDRG1-NEDD4 circuit has a critical role in receptor degradation, drug response, and resistance mechanism. Our studies offer a preclinical proof of concept for a strategy of cotargeting the EGFR and PYK2/FAK kinases to improve TNBC therapy. Cancer Res; 77(1); 86-99. ©2016 AACR.
TCT-369 The CLOSER Trial: A Multicenter Study on the Clinical Safety and Effectiveness of Closer™ VSS, a Novel Resorbable Transfemoral Vascular Access Sealing System
Authors: S. Chiu Wong, Roger Gammon, William Bachinsky, Charles O'Shaughnessy, Wayne Leimbach, Nelson Bernardo, Nick Cavros, Michael Jaff, Geoffrey Bergman
Journal: Journal of the American College of Cardiology (2016)
Cardiac safety of extensively drug-resistant tuberculosis regimens including bedaquiline, delamanid and clofazimine
Authors: Marina Tadolini, Rangjung Dolma Lingtsang, Simon Tiberi, Martin Enwerem, Lia D'Ambrosio, Tsetan Dorji Sadutshang, Rosella Centis, Giovanni Battista Migliori
Journal: European Respiratory Journal (2016)

We read with great interest the comments by R.S. Wallis on our article describing the first case of extensively drug-resistant tuberculosis (XDR-TB) treated with both delamanid and bedaquiline [1], as recommended by the European Respiratory Society hosted TB Consilium experts [2, 3]. First case, concerns and challenges of treatment of severe XDR-TB with both delamanid and bedaquiline <http://ow.ly/8e4l303i0LH>
Molecular Pathways: The eIF4F Translation Initiation Complex—New Opportunities for Cancer Treatment
Authors: Hélène Malka-Mahieu, Michelle Newman, Laurent Désaubry, Caroline Robert, Stéphan Vagner
Journal: Clinical Cancer Research (2016)

Abstract The eIF4F complex regulates the cap-dependent mRNA translation process. It is becoming increasingly evident that aberrant activity of this complex is observed in many cancers, leading to the selective synthesis of proteins involved in tumor growth and metastasis. The selective translation of cellular mRNAs controlled by this complex also contributes to resistance to cancer treatments, and downregulation of the eIF4F complex components can restore sensitivity to various cancer therapies. Here, we review the contribution of the eIF4F complex to tumorigenesis, with a focus on its role in chemoresistance as well as the promising use of new small-molecule inhibitors of the complex, including flavaglines/rocaglates, hippuristanol, and pateamine A. Clin Cancer Res; 23(1); 21–25. ©2016 AACR.
Official statistics show more deaths in patients admitted to hospital at weekends
Authors: Nigel Hawkes
Journal: BMJ (2016)

Patients admitted to an NHS hospital in England at the weekend in 2015-16 were 15% more likely to die within 30 days than those admitted during the week, an official analysis of the statistics shows.1

Furthermore, those discharged at the weekend were more likely to be readmitted as an emergency within seven days, and Sunday discharge was associated with a 40% higher readmission rate than discharge on a Wednesday. Friday and Saturday discharges were also linked to increased readmission rates, by 9% and 27%, respectively.

The mortality rates calculated by NHS Digital (formerly the Health and Social Care Information Centre) were very similar to those of Nick Freemantle and colleagues published in The BMJ ,2 which is not surprising, as the same methodology was used. The readmission data were new, and NHS Digital has produced tables …
Phase II study of gefitinib in metastatic or locoregionally recurrent nasopharyngeal carcinoma (NPC)
Authors: A. T. Chan, B. Ma, E. P. Hui, A. King, M. Kam, W. H. Kwan, T. Mok, S. F. Leung
Journal: Journal of Clinical Oncology (2006)

15509 Background: Our preclinical work has shown that epidermal growth factor receptor (EGFR) is expressed in ∼ 80% of undifferentiated NPC &amp; gefitinib is a small molecule inhibitor against EGFR with anti-proliferative activity in NPC in vitro. Methods: We report the preliminary result of a phase II study of gefitinib in patients (pts) who progressed after 1–2 lines of chemotherapy (at least 1 line had to contain platinum) for metastatic or locoregionally recurrent NPC. Fourteen Chinese pts were accrued, of whom the median age was 48 years (range 34–64 years), 12 were males, 9 had metastatic &amp; 5 had locoregionally recurrent NPC. All received gefitinib at 500mg/day orally, every 28 days with radiological assessment performed every 2 cycles for a maximum of 8 cycles. Ten pts had 1 line &amp; 5 pts had 2 lines of prior chemotherapy. Results: The median number of administered cycles was 2 (range 1–8). Of the 14 pts evaluable for toxicity, the most commonly reported were acneiform rash (86%, grade 1–2, n = 10; grade 3, n = 4), dry skin (86%, grade 1–2), diarrhea (71%, grade 1–2), fatigue (64%, grade 1–2), anorexia (64%, grade 1–2) &amp; nausea (20%, grade 2). Other grade 3–4 toxicities included fever (n = 2, skin cellulitis, infective pneumonia), hyponatremia (n = 2), near-syncope (n = 2), anemia (n = 1). Dose reduction to 250mg/day was required in 4 pts who encountered grade 3 skin rash. Of the 11 pts evaluable for response, 2 had stable disease (SD) for ≥ 6 months (m) (mean 6.8 m) 9 progressed and no partial responders. Five pts have died mostly of progressive disease &amp; there were no treatment-related deaths. Conclusions: Gefitinib is well tolerated in pts with advanced NPC with some pts experiencing disease stabilization for over 6 months &amp; study accrual is ongoing. No significant financial relationships to disclose.
TCT-726 Aortic Valve Replacement in Patients With Prior Mediastinal Radiation: Transcatheter Vs Surgical Approach
Authors: Julius I. Ejiofor, Anju Nohria, Anthony Norman, Siobhan McGurk, Douglas Shook, Charles Nyman, Piotr Sobieszczyk, Pinak Shah, Prem Shekar, Marc Pelletier, Tsuyoshi Kaneko
Journal: Journal of the American College of Cardiology (2016)
TCT-560 Novel Predictor of Target Vessel Revascularization after Coronary Stent Implantation: Intraluminal Intensity of Blood Speckle on Intravascular Ultrasound
Authors: Yuichi Saito, Hideki Kitahara, Takashi Nakayama, Yoshihide Fujimoto, Yoshio Kobayashi
Journal: Journal of the American College of Cardiology (2016)
TCT-92 SHORT- AND LONG-TERM REMODELING OF PULMONARY ARTERIES AFTER BALLOON ANGIOPLASTY IN PATIENTS WITH INOPERABLE CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION
Authors: Nicolay Danilov, Yura Matchin, Sergey Yarovoy, Olesya Sagaydak, Tamila Martynyuk, Irina Chazova
Journal: Journal of the American College of Cardiology (2016)
Commemorating Toxicology at the National Institute of Environmental Health Sciences on the Occasion of Its 50th Anniversary
Authors: John R. Bucher, Linda S. Birnbaum
Journal: Environmental Health Perspectives (2016)

Summary:In 1978, the National Toxicology Program (NTP) was established and headquartered at the National Institute of Environmental Health Sciences (NIEHS) in Research Triangle Park, North Carolina. On the occasion of the 50th Anniversary of the NIEHS, this article documents some of the historical and current NTP programs and scientific advances that have been made possible through this long-standing relationship.
RESULTADOS A LARGO PLAZO DEL DRENAJE DE VESÍCULA BILIAR GUIADO POR ECOENDOSCOPIA MEDIANTE PRÓTESIS DE APOSICIÓN LUMINAL CON CARÁCTER DEFINITIVO
Authors: I Peñas Herrero, R Sánchez-Ocaña, M Cimavilla Román, R Torres Yuste, R Amo Alonso, AL Loza Vargas, M De Benito, J Santos Fernández, C De La Serna, M Pérez-Miranda
Journal: Endoscopy (2016)

Introducción: En pacientes de alto riesgo con colecistitis puede emplearse el drenaje de vesícula biliar guiado por ecoendoscopia (DVB-USE) con carácter temporal o definitivo. Las nuevas prótesis de aposición luminal (PAL) parecen idóneas para el DVB-USE definitivo, pero no hay datos sobre su seguridad por encima de un año de seguimiento.
Global Identification of Genomic Structural Variants In Childhood ETV6/RUNX1 (TEL/AML1) Acute Lymphoblastic Leukemias by Mate-Pair Massively Parallel Sequencing.
Authors: Vera Okpanyi, Christoph Bartenhagen, Michael Gombert, Vera Binder, Hans-Ulrich Klein, Silja Roettgers, Jochen Harbott, Martin Dugas, Arndt Borkhardt
Journal: Blood (2010)
TCT-91 Efficacy of aggressive balloon pulmonary angioplasty on chronic thromboembolic pulmonary hypertension beyond normalized mean pulmonary arterial pressure
Authors: Yuto Shinkura, Kazuhiko Nakayama, Takayoshi Toba, Hachidai Takahashi, Daisuke Terashita, Kenzo Uzu, Koji Kuroda, Natsuko Tahara, Yoshinori Nagasawa, Yuichiro Nagano, Hiroyuki Yamamoto, yoshiro tsukiyama, Kenichi Yanaka, Naoki Tamada, Hiromasa Otake, Toshiro Shinke, Noriaki Emoto, Ken-ichi Hirata
Journal: Journal of the American College of Cardiology (2016)
Macrolides, inflammation and the lung microbiome: untangling the web of causality
Authors: Robert P Dickson, Alison Morris
Journal: Thorax (2016)

In the past decade, our understanding of the microbiology of the respiratory tract has been revolutionised by the introduction of culture-independent techniques of microbial identification.1 The lungs, once considered sterile in the absence of infection, have been consistently shown to contain diverse microbial communities, even in health.2 One consistent observation in the field is that in virtually every comparison to date, lung microbiota of healthy subjects differ from the lung microbiota of patients with acute and chronic lung disease. Yet, the field faces a crucial and challenging question: Are bacterial communities in the lung altered because of respiratory disease, or are our patients' lungs diseased because of their altered bacterial communities?

Sorting out cause and effect here is an intimidating task: the microbiome and the host response are so tightly entwined that trying to isolate the effects of each is difficult, both practically and conceptually. Most studies to date in the nascent lung microbiome field have been retrospective and descriptive, replete with provocative correlations, but silent on the direction of causality. Few longitudinal studies have provided the means of determining temporally whether dysbiosis arises before lung disease or vice versa. Given the long chronicity and unpredictability of many lung diseases, prospective cohort studies would need to be impractically large and lengthy to determine temporal precedence. Though animal models hold promise to help unravel mechanisms of pathogenesis3 ,4 characterising the lung microbiota of small animals is technically challenging, and the relevance of animal-associated microbiota to human respiratory health is far from obvious. Some innovative recent studies have attempted ‘lung microbiome transplants’ between diseased and non-diseased animals4 ,5 though it has not been established how much of the effect of this exposure is attributable to transferred microbiota and …
TCT-352 Proportion of Ischemic Risk After PCI Mediated by High Platelet Reactivity on Clopidogrel: Analysis From the ADAPT-DES Study
Authors: Bjorn Redfors, Ori Ben-Yehuda, Sheng-Hsuan Lin, Ariel Furer, Ajay Kirtane, Bernhard Witzenbichler, Giora Weisz, Thomas Stuckey, Akiko Maehara, Philippe Généreux, Gennaro Giustino, Michael Rinaldi, Franz-Josef Neumann, D. Christopher Metzger, Timothy Henry, David Cox, Peter L. Duffy, Ernest Mazzaferri, Girma Ayele, Roxana Mehran, Gary Mintz, Gregg Stone
Journal: Journal of the American College of Cardiology (2016)
TCT-662 Outcomes after TAVR in high-risk patients beyond 6 years
Authors: Magdalena Erlebach, Marcus-André Deutsch, Melchior Burri, Johannes Ziegelmueller, Domenico Mazzitelli, Hendrik Ruge, Markus Krane, Ruediger Lange, Sabine Bleiziffer
Journal: Journal of the American College of Cardiology (2016)
EXPERIENCIA EN EL TRATAMIENTO DEFINITIVO DEL PANCREAS DIVISUM (PD) CAUSANTE DE PANCREATITIS AGUDA DE REPETICION (PAR) MEDIANTE CPRE
Authors: J Mostazo Torres, IL Pinazo Martinez, M Vilchez Jaimez
Journal: Endoscopy (2016)

El PD se debe a la falta de fusión de los conductos del páncreas dorsal y ventral embriológico. La mayor parte de las secreciones exocrinas se drenan a través del conducto de santorini y la papila minor al contrario que ocurre en los páncreas normales. La mayor parte de los pacientes con estas alteraciones se mantienen asintomáticos, pero en algunos existe alguna alteración en el drenaje de las secreciones causando PAR.
TCT-314 The impact of chronic kidney disease on outcomes following percutaneous coronary interventions versus coronary artery bypass grafting in patients with complex coronary artery disease: 5-year follow-up of the SYNTAX trial
Authors: Milan Milojevic, Stuart Head, Michael Mack, Friedrich Mohr, Marie-Claude Morice, Keith Dawkins, David Holmes, Patrick Serruys, A. Pieter Kappetein
Journal: Journal of the American College of Cardiology (2016)
TCT-533 Fractional Flow Reserve And Coronary Flow Reserve To Predict Outcomes in Coronary Artery Disease
Authors: Jung-Min Ahn, Se Hun Kang, Tae-Hoon Kim, Frederik Zimmermann, Nils Johnson, Eun-Seok Shin, Bon-Kwon Koo, Pil Hyung Lee, Duk-Woo Park, Soo-Jin Kang, Seung-Whan Lee, Young-Hak Kim, Cheol Whan Lee, Seong-Wook Park, Nico Pijls, Seung-Jung Park
Journal: Journal of the American College of Cardiology (2016)
PS01.10: Medically Underserved and Geographically Remote Individuals may be Underrepresented in Current Lung Cancer Screening Programs
Authors: Candice L. Wilshire, Bretta M. McCall, Hannah E. Modin, Joelle T. Fathi, Christopher R. Gilbert, Brian Louie, Ralph W. Aye, Alexander S. Farivar, Eric Vallieres, Jed A. Gorden
Journal: Journal of Thoracic Oncology (2016)
Interim Report of a Randomized, Open-Label, Multicenter Study to Evaluate the Safety and Efficacy of Decitabine As an Epigenetic Priming Agent When Combined with Induction Chemotherapy in Pediatric Patients (pts) with Newly Diagnosed Acute Myelogenous Leukemia (AML)
Authors: Lia Gore, Margaret E. Macy, Francoise Mechinaud, Aru Narendran, Frank Alvaro, Carola A.S. Arndt, Phillip Barnette, Jessica Boklan, Todd Cooper, Laura Martin, W Tcheng, Peter Tarassoff, Mark M Jones, Soheil Meshinchi, Robert J. Arceci
Journal: Blood (2012)
Pharmacokinetics (PK) and Pharmacodynamics (PD) of Palifermin (a r-huKGF molecule) in Healthy Volunteers after Intravenous Administration of Single Escalating Doses up to 250 mcg/kg.
Authors: Parnian Zia-Amirhosseini, Margaret Salfi, Philip Leese, John T. Sullivan
Journal: Blood (2004)
TCT-111 Relationship between anemia, prasugrel use and clinical outcomes in contemporary percutaneous coronary intervention for acute coronary syndromes
Authors: Jaya Chandrasekhar, Usman Baber, Samantha Sartori, Melissa Aquino, Michela Faggioni, Birgit Vogel, Serdar Farhan, J. Brent Muhlestein, Timothy Henry, Craig Strauss, Catalin Toma, William Weintraub, Sandra Weiss, Anthony DeFranco, Annapoorna Kini, Mark Effron, Brian Baker, Stuart Keller, Samir Kapadia, Stuart Pocock, Sunil Rao, Roxana Mehran
Journal: Journal of the American College of Cardiology (2016)
Phase I dose escalation study of fractionated stereotactic radiosurgery (fSRS) for recurrent squamous cell carcinoma of the head and neck (SCCHN)
Authors: D. E. Heron, R. L. Ferris, S. Burton, S. Lai, M. V. Karamouzis, W. Gooding, J. Johnson, R. P. Smith, A. Argiris, J. Grandis
Journal: Journal of Clinical Oncology (2007)

6029 Background: Limited-field re-irradiation has been used as salvage and palliative therapy in recurrent previously irradiated SCCHN. Its primary limitation is the dose to critical structures, such as the spinal cord. With its greater degree of conformality, accuracy and limited number of fractions (fx), extracranial fSRS has become an attractive alternative. Prior reports have used 25 Gy in 5 fx in recurrent SCCHN. This phase I trial assessed the safety of fSRS and established a starting dose for a planned phase II trial with concurrent cetuximab. Methods: Eligibe patients (pts) had pathologically-confirmed SCCHN that recurred post standard therapies, ECOG performance status 0–2, and measurable disease. All pts were staged and planned with PET-CT and were treated with the CyberKnife Frameless Radiosurgery System (Accuray, Sunnyvale, CA). Prior therapies included: radiation therapy (all pts, dose range: 50.4–88 Gy), surgery (n=22), chemotherapy (n=14). fSRS was delivered in 5 fx, every other day in 2 weeks, and dose escalated in successive cohort of 4 pts at 5 dose levels: I: 5 Gy/fx (25 Gy), II: 6.4 Gy/fx (32 Gy), III: 7.2Gy/fx (36 Gy), IV: 8 Gy/fx (40 Gy), and V: 8.8 Gy/fx (44 Gy). Dose limiting toxicities (DLT) was assessed up to 4-week period post fSRS. Dose tiers 4 and 5 were expanded to include more patients when no DLT were observed in the earlier cohorts. Results: 25 pts were enrolled and 19 were evaluable for response (tier I:4, II:4 III:3 IV:7 V:7). Median age 62 years (range 35–86), Male/Female: 24/1, 7 ECOG Performance status 0 (n=7), PS 1 (n=11), PS 2 (n=7). There were no DLTs observed to date. Toxicities included: grade 2 dysphagia (n=1) and grade 1 mucositis (n=2). Best responses: CR=1, PR=5, SD=9, PD=4 with an overall response rate of 31% (95% CI 13%-56%). Additionally, in this cohort with inoperable recurrent SCCHN 15/19 pts (79%) had stable or responding disease at last follow-up. The median survival was 24 weeks. Conclusions: Re-irradiation with fSRS is feasible and well tolerated up to a total dose of 44 Gy (8.8 Gy/fx). A phase II trial incorporating concomitant cetuximab is currently approved. No significant financial relationships to disclose.
Cytoprotective Palifermin Allowed Melphalan Dose Escalation to 280mg/2 for Multiple Myeloma Patients with Normal Renal Function Receiving Autologous Stem Cell Transplantation (ASCT) - Final Results of a Phase 1 Trial
Authors: Muneer H. Abidi, Nishant Tageja, Lawrence G. Lum, Judith Abrams, Zaid Al-Kadhimi, Lois Ayash, Simon Cronin, Marie Ventimiglia, Abhinav Deol, Voravit Ratanatharathorn, Joseph P. Uberti
Journal: Blood (2010)
Erythrocytosis in hepatocellular carcinoma portends poor prognosis by respiratory dysfunction secondary to mitochondrial DNA mutations
Authors: Shizhong Ke, Shuzhen Chen, Zihui Dong, Christopher S. Hong, Qi Zhang, Liang Tang, Pinghua Yang, Jian Zhai, Hexin Yan, Feng Shen, Zhengping Zhuang, Wen Wen, Hongyang Wang
Journal: Hepatology (2016)

Erythrocytosis is a common paraneoplastic syndrome associated with hepatocellular carcinoma. Although increased erythropoietin (EPO) is found in these patients, the clinical significance and molecular mechanisms underlying this observation are unclear. We demonstrate an inverse relationship between EPO production and overall prognosis in our cohort of 664 patients as well as in data from The Cancer Genome Atlas. In the subset of hepatocellular carcinoma patients with erythrocytosis, we identified somatic mutations of mitochondrial DNA, resulting in impairment of respiratory metabolism, which sequentially led to depletion of α-ketoglutarate, stabilization of hypoxia inducible factor-α, and expression of target genes such as EPO. Cell lines and patient-derived xenograft models were used to demonstrate that EPO promoted cancer stem cell self-renewal and expansion in an autocrine/paracrine manner through enhanced Janus kinase/signal transducer and activator of transcription signaling both in vitro and in vivo. Furthermore, to explore the therapeutic targeting of EPO-induced tumor changes, we found that blocking EPO signaling with soluble EPO receptor extracellular domain Fc fusion protein could inhibit tumor growth both in vitro and in vivo. Conclusion: These findings suggest clinical and therapeutic implications for erythrocytosis in hepatocellular carcinoma. There is an underlying link between mitochondrial function and hypoxia inducible factor alpha signaling, revealing a mechanism of erythrocytosis in a subset of hepatocellular carcinoma patients who may benefit from treatment involving EPO signaling interference. (Hepatology 2017;65:134-151).
TCT-71 The NIREUS Randomized Trial: 1-Year Results of the BioNIR Ridaforolimus-Eluting Coronary Stent System (BioNIR) EUropean Angiography Study
Authors: Pieter Smits, Ori Ben-Yehuda, Ioanna Kosmidou, M. Ozgu Ozan, Ovidiu Dressler, Michael Jonas, Shmuel Banai, Maciej Pruski, Yoram Richter, Gregg Stone
Journal: Journal of the American College of Cardiology (2016)
The IL-15 Superagonist ALT-803 Enhances NK Cell ADCC and in Vivo Clearance of B Cell Lymphomas Directed By an Anti-CD20 Monoclonal Antibody
Authors: Maximillian Rosario, Bai Liu, Lin Kong, Stephanie E Schneider, Emily K Jeng, Peter R Rhode, Hing Wong, Todd A Fehniger
Journal: Blood (2014)
UTILIDAD DE LA INDOMETACINA RECTAL EN LA PREVENCIÓN DE LA PANCREATITIS AGUDA POSTCPRE
Authors: AD Polanco Jimenez, A Lopez Serrano, CA Amurrio Gonzalez, A Pascual Romero, MJ Suarez Davalos, I Ortiz Polo, P Latorre Año, C Garcia Orts, J Hervas Martin, E Moreno Osset
Journal: Endoscopy (2016)

Introducción: La pancreatitis aguda es la complicación más frecuente de la CPRE. Diversos estudios, incluyendo las últimas guías de la Sociedad Europea de Endoscopia Gastrointestinal (ESGE), apoyan el uso de 100 mg de indometacina rectal para prevenir esta complicación; sin embargo, existe controversia acerca de su beneficio en la prevención de la pancreatitis aguda postCPRE (PAP).
Giant Cell Arteritis
Authors: Gary S. Hoffman
Journal: Annals of Internal Medicine (2016)

This issue provides a clinical overview of giant cell arteritis, focusing on diagnosis, treatment, and practice improvement. The content of In the Clinic is drawn from the clinical information and education resources of the American College of Physicians (ACP), including MKSAP (Medical Knowledge and Self-Assessment Program). Annals of Internal Medicine editors develop In the Clinic in collaboration with the ACP's Medical Education and Publishing divisions and with the assistance of additional science writers and physician writers.